| Autor: |
Osborne, N. N., Chidlow, G., Layton, C. J., Wood, J. P. M., Casson, R. J., Melena, J. |
| Předmět: |
|
| Zdroj: |
Eye; Nov2004, Vol. 18 Issue 11, p1075-1084, 10p |
| Abstrakt: |
CONCLUSIONS:A battery of agents now exist that can blunt animal ganglion cell death irrespective of whether the insult was to the ganglion cell body or the mylinated axon. Whether this information can be applied for use in patients remains a matter of debate, and major obstacles need to be overcome before the laboratory studies may be applied clinically. These include the delivery of the pharmacological agents to the site of ganglion cell injury and side effects to the patients. Moreover, it is necessary to establish whether effective neuroprotection is only possible when the drug is administered at a defined time after injury to the ganglion cells. This information is essential in order to pursue the idea that a neuroprotective strategy can be applied to a disease like glaucoma, where ganglion cell death appears to occur at different times during the lifetime of the patient.Eye (2004) 18, 1075-1084. doi:10.1038/sj.eye.6701588 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
